



Dimerix

(ASX:DXB)

Investor Presentation

February 2022

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

About Dimerix

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease

Advancing **three Phase 3** clinical studies

Demonstrated **clinical efficacy**¹; drug well understood, with **strong safety profile**¹

Patent protected products with **commercial manufacturing** established

Strong outlook with potential for **significant value**² upside



Corporate overview



Ticker Symbol

ASX:DXB



Cash Balance
(31Dec21)

A\$16.3 million



Market
Capitalisation

~A\$75 million



Share price

~A\$0.24



Total ordinary
shares on issue

320,873,666



Average volume

1,177,054



Top 20
Shareholders own

35%

Share price

Chart generated on 24/2/2022 at 9:34 am



Top shareholders

Position	Holder Name	Holding	% IC
1	Mr Peter Meurs	44,179,309	13.8%
2	Merchant Group & Nominees	17,925,000	5.6%
3	Mr Andrew & Mrs Melinda Coates	8,100,000	2.5%
4	Bavaria Bay Pty Ltd	7,316,992	2.3%
5	Yodambao Pty Ltd	6,362,603	2.0%
6	Solequest Pty Ltd & Nominees	3,387,302	1.1%
7	Pfleger Family A/C & Nominees	3,137,874	1.0%
8	Tamer Yigit Property Group Pty Ltd	3,101,343	1.0%
9	Rubi Holdings Pty Ltd	2,500,000	0.8%
10	Jampaso Pty Ltd and Nominees	2,377,355	0.7%
TOTAL (TOP 10)		98,387,778	30.7%

Development pipeline

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Key milestones
DMX-200	Focal Segmental Glomerular Sclerosis (FSGS)					Phase 2a demonstrated encouraging efficacy & safety ¹ ; Phase 3 underway with regulatory &/or ethics authorisation in multiple countries ² , recruitment of 1 st patients planned Q1 22, 1 st interim data anticipated H1 23 ³
	Diabetic Kidney Disease					Phase 2 demonstrated promising efficacy and safety ¹ , planning of next study design underway
	Late COVID pneumonia – REMAP-CAP					Recruitment underway across Europe ⁴ , initial data anticipated Q1 22 ³
	Early COVID respiratory – CLARITY 2.0					Recruitment underway across India ⁵ , ethics approval in Australia ⁶ , interim data from India anticipated Q1 22 ³
DMX-700	Chronic Obstructive Pulmonary Disease (COPD)					Pre-clinical studies underway to support entry into clinical studies; data anticipated Q2 22
DMX-xxx	Undisclosed (multiple)					Additional target opportunities identified using Receptor-HIT; preliminary exploratory work underway

¹ ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21

² ASX releases: 21Oct21, 01Feb22 (Australia, Denmark); + Taiwan approved on 08Feb22

³ Subject to recruitment

⁴ ASX release: 23Apr21, 16Dec21

⁵ ASX release: 11Jan22

⁶ ASX release: 23Dec21

For personal use only



Kidney Disease Development Overview



FSGS: unmet need and market potential

Focal = some
Segmental = sections
Glomerulo = of the kidney filtering units
Sclerosis = are scarred

~40,000

people in the
US are
diagnosed with
FSGS¹

>5,400

patients in the
US are
diagnosed with
FSGS each year¹

>US\$7,000

cost of average
orphan drug per
month in US⁵
(US\$84,000/yr)

50%

of patients with
FSGS will
progress to
kidney failure²

20,000

FSGS patients in
US have kidney
failure²

~1000

FSGS patients in
US receive a
kidney
transplant each
year²

60%

patients have
reoccurring
FSGS after first
kidney
transplant³

20%

of child
nephrotic
syndrome cases
caused by
FSGS²

2x

more common
in males⁴

5x


higher
incidence in
black patients⁴

No therapies yet approved for FSGS

FSGS phase 3 study design



A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB



FSGS phase 3 study locations



A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB


Global study with ~70 sites in 12 countries:

Country	Regulatory and/or ethics approval to proceed
Australia	✓
Argentina	✓
Brazil	
Denmark	✓
France	✓
Hong Kong	
New Zealand	✓
South Korea	
Spain	
Taiwan	✓
UK	
USA	

DMX-200 Intellectual property and exclusivity



COVID-19 Respiratory Complications



COVID-19 and pneumonia market potential

For personal use only

3 million

deaths annually caused
by lower respiratory
tract infections
pre-COVID*



US\$17 billion

pre-COVID: Pneumonia
responsible for US\$17
billion in healthcare
costs each year in the
US¹

US\$18.5 billion

market forecast
expected by 2029,
growing at 10%/year³

4.5 million:

COVID-19: caused 219
million cases globally to
date, resulting in >4.5
million deaths and
counting²

20-30%

of all patients with
pneumonia require
admission to Intensive
Care Units¹



\$ 2,300-4,600

The cost of treatment
with Tocilizumab (IL-6
receptor antagonist
used for COVID-19):
IV single dose⁴

1. REMAP-CAP background: <https://www.remapcap.org/background>

2. WHO COVID dashboard: <https://covid19.who.int/>


3. Data Bridge Market Research 2022, <https://www.databridgemarketresearch.com/reports/global-acute-respiratory-distress-syndrome-ards-market>

4. Dose and therefore cost varies with patient weight; Pharmacoeconomics & Outcomes News 2021; volume 879, p.28

Potential benefits of DMX-200



Antiviral medications:
Typically effective at preventing damage caused by a virus when administered within 3-5 days of infection¹
when many are asymptomatic




DMX-200:
Does not rely on early inhibition of viral replication
—
DMX-200 aims to prevent damaging immune response regardless of vaccination or antiviral treatment



DMX-200:
May be beneficial for patients with a wide range of respiratory diseases in addition to COVID²
Antivirals are usually very specific for a virus and sometimes even the particular strain of the virus¹

Two Phase 3 studies in COVID-19 patients



REMAP-CAP: COVID-19 pneumonia in ICU

- >750 patients recruited to the study domain
- WHO endorsed study
- Primary endpoint = 21 day mortality



Funded by European Union through H2020
“Rapid European COVID-19 Emergency
Research response” (RECOVER) project



CLARITY 2.0: COVID-19 respiratory complications

- Recruiting >600 patients in India and Australia
- Primary endpoint = 14 day WHO Clinical Health Score

Run through the NHMRC Clinical trials centre and the University
of Sydney

Secondary endpoint: recovery and quality of life
post hospitalisation (long-COVID assessment)



Initial study data anticipated Q1 2022



A biopharmaceutical
developing innovative
in areas with unmet




Drug

Additional longer term propositions

Additional asset value propositions

Longer term opportunities



DMX-200
Diabetic Kidney
Disease

Addressable market
US\$1.1 billion*

Key driver is the rise in diabetes global incidence

Diversifying
risk and
potential
sources of
revenue

DMX-700
Chronic Obstructive
Pulmonary Disease

Global COPD treatment market (2017)
US\$14 billion**



For personal use only



Corporate Outlook

Potential value driving events

2021

2022

- ✓ DMX-200 demonstrated **encouraging clinical efficacy** and **strong safety profile** across multiple Phase 2 renal clinical studies
- ✓ Consistent advice received from **FDA, EMA and UK MHRA** on FSGS Phase 3 study design
- ✓ Orphan Drug Designation/**accelerated approval pathway** granted by US FDA, EU EMA and UK MHRA for FSGS
- ✓ Two independent Phase 3 clinical studies underway in patients with **COVID-19 respiratory complications**
- ✓ DMX-200 **manufacturing process optimised** to improve commercial scalability and global logistics
- ✓ DMX-700 in COPD progressed further towards **clinical development**
- ✓ Expansion of **IP portfolio**
- ✓ Strong **financial position**

- ✓ FSGS **ethics approval** and clinical **site initiations**
- ☐ FSGS Phase 3 study **recruitment** and first patient **first dose**
- ☐ REMAP-CAP Phase 3 COVID-19 study recruitment and **top line data**
- ☐ CLARITY 2.0 Phase 3 COVID-19 study recruitment and **top line data**
- ☐ DMX-700 for Chronic Obstructive Pulmonary Disease progression towards **clinical study**
- ☐ Diabetic kidney disease **clinical study** design and next steps
- ✓ Further expansion of **IP portfolio**
- ☐ FSGS **Phase 3 study Part 1 analysis** and progression to Part 2



Dimerix

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

Advancing three Phase 3 opportunities

Well positioned to deliver against strategic plan

Dimerix HQ

425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.

For personal use only




Dimerix

Appendix

Phase 2a trial in FSGS completed


Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Primary Focal Segmental Glomerulosclerosis who are Receiving Irbesartan

- *Primary endpoint: safety. Secondary endpoint: proteinuria and biomarker analysis.*
- *Patient population: Patients with primary FSGS who are receiving irbesartan*



DMX-200 inflammatory biomarker


Average baseline MCP-1 versus
average baseline proteinuria




DMX-200 Phase 2 study confirmed
high MCP-1 correlates to high
proteinuria in FSGS patients

DMX-200 PCR summary

Change in uPCR over time on
DMX-200 versus placebo
(repeat measures mixed model)



Change in MCP-1 over time on
DMX-200 versus placebo




16 weeks treatment with DMX-200 vs placebo:

- **17% reduction of uPCR:** mixed model, repeat measures statistical test; (*grouped analysis model shows a 25% drop in uPCR*)
- **39% reduction inflammatory biomarker MCP-1:**
 - DMX-200 blocks receptor responsible for inflammation
 - translates to reduced inflammation and subsequent fibrosis (scarring) in the kidney

DMX-200 treatment group met primary and secondary endpoints

Average reduction in proteinuria after 16 weeks treatment on DMX-200 versus placebo compared to standard of care alone in FSGS patients¹



- DMX-200 demonstrated clear benefit to patients with FSGS
 - 86% of patients demonstrated reduced proteinuria on DMX-200 versus placebo
 - 29% of patients demonstrated >40% reduction in proteinuria
 - Results comparable to other compounds in development²
- DMX-200 was safe and well-tolerated
- DMX-200 may be complementary to other development compounds, such as sparsentan³

No safety concerns – reduced development risk
DMX-200 compares favourably to compounds currently in development^{2,4}



PCR = protein creatinine ratio
ARB = angiotensin receptor blocker
1. Repeated measures mixed model analysis; top line data was reported as grouped analysis
2. Trachtman, et al., 2018. J Amer Soc Nephrology 29(11):2745-2754
3. ASX release 24Mar21
4. Based on: a) <https://lupkynispro.com/safety/>; b) <https://www.reatapharma.com/investors/news/news-details/2021/Reata-Pharmaceuticals-Announces-Outcome-of-FDA-Advisory-Committee-Meeting-of-Bardoxolone-for-the-Treatment-of-Patients-with-Chronic-Kidney-Disease-Caused-by-Alport-Syndrome/default.aspx>; c) <https://pubmed.ncbi.nlm.nih.gov/31343124/>; <https://www.goldfinchbio.com/news-features/goldfinch-bio-presents-clinical-data-from-phase-1-trial-supporting-advancement-of-gfb-887-as-a-precision-medicine-for-patients-with-kidney-diseases/>